Which term describes the ongoing collection of data on the safety of medicines after they've been marketed?

Which term describes the ongoing collection of data on the safety of medicines after they've been marketed?

• A. Pharmacoeconomics
• B. Pharmacovigilance
• C. Pharmacokinetics
• D. Pharmacogenomics

Answer: (B)

Ongoing collection of data on the safety of medicines after they've been marketed is pharmacovigilance. It involves monitoring reports of adverse drug reactions, detecting safety signals, and taking actions to minimize risk, such as updating labeling or conducting post-marketing studies to understand how a drug performs in real-world use. This continuous surveillance goes beyond pre-approval trials, which can be limited in size and duration, to protect patients over the long term. Pharmacoeconomics, by contrast, deals with the cost and value of drugs; pharmacokinetics examines how the body absorbs, distributes, metabolizes, and eliminates a drug; and pharmacogenomics studies how genetic differences influence drug response. These areas are not focused on post-marketing safety surveillance.

Ongoing collection of data on the safety of medicines after they've been marketed is pharmacovigilance. It involves monitoring reports of adverse drug reactions, detecting safety signals, and taking actions to minimize risk, such as updating labeling or conducting post-marketing studies to understand how a drug performs in real-world use. This continuous surveillance goes beyond pre-approval trials, which can be limited in size and duration, to protect patients over the long term.

Pharmacoeconomics, by contrast, deals with the cost and value of drugs; pharmacokinetics examines how the body absorbs, distributes, metabolizes, and eliminates a drug; and pharmacogenomics studies how genetic differences influence drug response. These areas are not focused on post-marketing safety surveillance.